Mantle Cell Lymphoma

Leo I. Gordon, MD, discusses the evolution of the treatment paradigm in relapsed/refractory mantle cell lymphoma.

Alexey Danilov, MD, PhD, discusses ongoing investigations taking place to improve the treatment of patients with mantle cell lymphoma.

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Jean L. Koff, MD, MS, discusses the role of covalent BTK inhibitors in the treatment of mantle cell lymphoma.

Manali Kamdar, MD, discusses which populations of lymphoma subtypes, such as MCL, may derive the most benefit from liso-cel treatment.

Manali Kamdar, MD, discusses responses with liso-cel according to prior lines of therapy and BTK inhibitor exposure in mantle cell lymphoma.

Orelabrutinib in combination with lenalidomide and rituximab was safe and active in treatment-naive mantle cell lymphoma.

The combination of ibrutinib, lenalidomide, and rituximab elicited a high response rate in patients with relapsed/refractory mantle cell lymphoma.

Alexey Danilov, MD, PhD, highlights non-chemotherapy options for the treatment of mantle cell lymphoma and expands on ongoing research in hematologic malignancies.

Rituximab maintenance therapy following frontline bendamustine plus rituximab improved EFS, EFS2, and OS vs no maintenance therapy in patients with MCL.

Ibrutinib plus venetoclax produced durable complete responses in TP53-mutated mantle cell lymphoma.

Tycel Phillips, MD, expands on the treatment paradigm for patients with mantle cell lymphoma, highlighting recent data read-outs and FDA approvals/withdrawals

Alexey Danilov, MD, PhD, discusses the evolution of treatment for patients with mantle cell lymphoma.

Tycel Phillips, MD, highlights key takeaways in NHL, MDS, and myelofibrosis from an OncLive State of the Science Summit on hematology.

Liso-cel demonstrated clinically meaningful activity regardless of the number of previous lines of systemic therapy or response to prior BTK inhibitors in MCL.

Frontline zanubrutinib/rituximab induction followed by short-course chemotherapy yielded efficacy in mantle cell lymphoma.

Tycel Phillips, MD, discusses updated findings from a phase 1/2 trial evaluating glofitamab in relapsed/refractory mantle cell lymphoma.

Frontline treatment with acalabrutinib and bendamustine/rituximab (BR) improved PFS over BR alone in older patients with mantle cell lymphoma.

The combination of zanubrutinib, obinutuzumab, and venetoclax was safe and well-tolerated in older patients with untreated mantle cell lymphoma.

Clinically meaningful activity was found across all subgroups in a posthoc subgroup analysis of patients with MCL treated with liso-cel.

Here is your guide to important regulatory approvals made by the FDA in May 2024.

The FDA approved liso-cel for the treatment of adult patients with relapsed/refractory mantle cell lymphoma after at least 2 prior lines of therapy, including a BTK inhibitor.

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

CAR T-cell therapy is effective and tolerable in patients with mantle cell lymphoma with secondary central nervous system involvement.

Jean L. Koff, MD, MS, discusses key considerations in the choice of BTK inhibitors for frontline and maintenance treatment in MCL.